Private company

NAVIDEA BIOPHARMACEUTICALS, INC.

NAVIDEA BIOPHARMACEUTICALS, INC. is an American in vitro and in vivo diagnostic substances company based in Dublin.2

Last updated Oct 20, 2026.

Overview

  • IndustryIn Vitro & In Vivo Diagnostic Substances2
  • HeadquartersDublin, United States2
  • Incorporated inDE3
  • Business address4995 Bradenton Avenue, Suite 240, Dublin, Oh 430173
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300HXUMV6VNCPEE052
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Registered Agent Solutions, Inc., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 21591352

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-181.7%Gross margin4
-21402.1%Operating margin4
-23117.6%Net margin4
-87.6%Revenue growth, 20224
-$9.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue0¢$1.9K
  • Research and development43¢$6.0M
  • Selling, general and admin57¢$8.0M

Out of $65.7K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$65.7K in 2022−99% since 2016
0$2.0M$4.0M$6.0M2016: $5.0M$5.0M20162017: $1.8M$1.8M2017−64%2018: $1.2M$1.2M2018−35%2019: $657.8K$657.8K2019−44%2020: $915.0K$915.0K2020+39%2021: $531.5K$531.5K2021−42%2022: $65.7K$65.7K2022−88%
Gross profit567894-$119.3K in 2022
-$2.0M0$2.0M$4.0M$6.0M2016: $4.9M$4.9M20162017: $1.8M$1.8M2017−63%2018: $1.1M$1.1M2018−41%2019: $651.2K$651.2K2019−39%2020: $914.0K$914.0K2020+40%2021: $531.5K$531.5K2021−42%2022: -$119.3K-$119.3K2022
Operating income567894-$14.1M in 2022+38% since 2016
-$15.0M-$10.0M-$5.0M02016: -$10.1M-$10.1M20162017: -$13.9M-$13.9M2017+37%2018: -$10.8M-$10.8M2018−22%2019: -$11.0M-$11.0M2019+1%2020: -$10.7M-$10.7M2020−2%2021: -$12.1M-$12.1M2021+13%2022: -$14.1M-$14.1M2022+17%
Net income1067894-$15.2M in 2022+6% since 2016
-$25.0M0$25.0M$50.0M$75.0M2016: -$14.3M-$14.3M20162017: $74.9M$74.9M20172018: -$16.1M-$16.1M20182019: -$10.9M-$10.9M2019−32%2020: -$10.7M-$10.7M2020−2%2021: -$11.7M-$11.7M2021+9%2022: -$15.2M-$15.2M2022+29%
Fiscal year2016201720182019202020212022
Revenue$5.0M5$1.8M6$1.2M7$657.8K8$915.0K9$531.5K4$65.7K4
Cost of revenue$62.3K5$3.7K6$96.6K7$6.7K8$1.0K9$04$1.9K4
Gross profit$4.9M5$1.8M6$1.1M7$651.2K8$914.0K9$531.5K4-$119.3K4
Research and development$7.1M5$4.5M6$4.2M7$5.3M8$4.9M9$5.1M4$6.0M4
Selling, general and admin$7.9M5$11.2M6$7.7M7$6.3M8$6.7M9$7.5M4$8.0M4
Operating expenses$12.6M4$13.9M4
Operating income-$10.1M5-$13.9M6-$10.8M7-$11.0M8-$10.7M9-$12.1M4-$14.1M4
Interest
Income before tax-$11.7M4-$15.2M4
Income tax$010-$4.1M6-$9.8K7$7078$09$16.0K4$04
Net income-$14.3M10$74.9M6-$16.1M7-$10.9M8-$10.7M9-$11.7M4-$15.2M4
Earnings per share-$0.095$0.476-$0.096-$0.404-$0.564
Earnings per share (diluted)-$0.095$0.456-$0.096
Shares (weighted, basic)29.3M shares430.9M shares4

Compare NAVIDEA BIOPHARMACEUTICALS, INC. with another company

Corporate structure

NAVIDEA BIOPHARMACEUTICALS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NAVIDEA BIOPHARMACEUTICALS, INC.

  • John K. Scott Jr. Filed SC 13D/A on NAVIDEA BIOPHARMACEUTICALS, INC., latest Feb 5, 2024 (8 filings since Apr 22, 2022)
  • Irwin Allen Bain Filed SC 13G/A on NAVIDEA BIOPHARMACEUTICALS, INC., latest Jul 3, 2023 (3 filings since Oct 6, 2022)
  • NAVIDEA BIOPHARMACEUTICALS, INC. Dublin, Ohio, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What NAVIDEA BIOPHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$835.8K4 Dec 31, 2022$866.3K4 Dec 31, 2021−3.5%
Accumulated depreciation$700.5K4 Dec 31, 2022$745.8K4 Dec 31, 2021−6.1%
Property and equipment, net$135.3K4 Dec 31, 2022$120.5K4 Dec 31, 2021+12.3%
Operating-lease assets (leased space)$20.3K4 Dec 31, 2022$128.2K4 Dec 31, 2021−84.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.0M4 Dec 31, 2022$4.2M4 Dec 31, 2021−52.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$1.2M4 Dec 31, 2022$953.4K4 Dec 31, 2021+27.5%
Accumulated amortization$215.4K4 Dec 31, 2022$167.8K4 Dec 31, 2021+28.4%
Finite-lived intangibles, net$1.0M4 Dec 31, 2022$785.7K4 Dec 31, 2021+27.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$427.3K4 Dec 31, 2022$151.2K4 Dec 31, 2021+182.7%
Raw materials$27.4K4 Dec 31, 2022$50.0K4 Dec 31, 2021−45.2%
Work in process$399.9K4 Dec 31, 2022$04 Dec 31, 2021
Finished goods$131.8K4 Dec 31, 2022$101.2K4 Dec 31, 2021+30.3%

Leadership

Who has led NAVIDEA BIOPHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David C. Bupp2006–2011
  2. Mark Jerome Pykett2011–2014
  3. Ricardo J. Gonzalez2014
  4. Michael M. Goldberg2016–2017
  5. Jed Latkin2019–2021

President

  1. David C. Bupp2006–2011
  2. Thomas H. Tulip2014
  3. Michael M. Goldberg2016–2017

Chief financial officer

  1. Brent L. Larson2006–2016
  2. Jed Latkin2017–2021
  3. Craig Dais2023

Chief operating officer

  1. Jed Latkin2016–2021
2010201520202025
Board members and other officers (42)

Former names

  • NEOPROBE CORPFeb 10, 1995 to Dec 30, 20113

Timeline

  1. Dec 1, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares62
  2. Nov 16, 20238-K Entered a material agreement; Unregistered sale of shares; Executive or director change63
  3. Aug 8, 20238-K Executive or director change64
  4. Jul 28, 20238-K Executive or director change; Shareholder vote; Other events65
  5. Jul 13, 20238-K Executive or director change66
  6. Jul 6, 20238-K Entered a material agreement; Unregistered sale of shares; Other events67
  7. Jun 16, 20238-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure68
  8. Jun 16, 20238-K Entered a material agreement; Other events69
  9. Jun 5, 20238-K Entered a material agreement; Listing notice or transfer; Unregistered sale of shares70
  10. May 25, 20238-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed71
  11. Apr 28, 20238-K Entered a material agreement; New debt or obligation; Other events72
  12. Apr 13, 20238-K Entered a material agreement73
  13. Feb 11, 2019New chief executive Jed Latkin becomes CEO13
  14. Oct 19, 2016New chief executive Michael M. Goldberg becomes CEO14
  15. Oct 15, 2014New chief executive Ricardo J. Gonzalez becomes CEO15
  16. Aug 23, 2011New chief executive Mark Jerome Pykett becomes CEO16
  17. May 31, 2006New chief executive David C. Bupp becomes CEO17
  18. Apr 28, 1988Founded NAVIDEA BIOPHARMACEUTICALS, INC. is founded2

Calendar

When it reported results

  1. Mar 21, 2023Reported quarterly or annual results74
  2. Nov 15, 2022Reported quarterly or annual results75
  3. May 12, 2022Reported quarterly or annual results76
  4. Mar 23, 2022Reported quarterly or annual results77
  5. Nov 10, 2021Reported quarterly or annual results78

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

192 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 34 major events, 79 insider forms, 11 large holders, 59 other. The latest 20:

  1. Feb 5, 2024SC 13D/A EDGAR
  2. Jan 31, 2024EFFECT EDGAR
  3. Jan 31, 2024EFFECT EDGAR
  4. Jan 31, 2024EFFECT EDGAR
  5. Jan 31, 2024EFFECT EDGAR
  6. Jan 31, 2024EFFECT EDGAR
  7. Jan 26, 2024S-8 POS EDGAR
  8. Jan 26, 2024S-8 POS EDGAR
  9. Jan 26, 2024S-8 POS EDGAR
  10. Jan 26, 2024S-8 POS EDGAR
  11. Jan 26, 2024POS AM EDGAR
  12. Jan 26, 2024S-8 POS EDGAR
  13. Jan 26, 2024POS AM EDGAR
  14. Jan 26, 2024S-8 POS EDGAR
  15. Jan 26, 2024POS AM EDGAR
  16. Jan 26, 2024S-8 POS EDGAR
  17. Jan 26, 2024POS AM EDGAR
  18. Jan 26, 2024S-8 POS EDGAR
  19. Jan 26, 2024POS AM EDGAR
  20. Jan 26, 2024S-8 POS EDGAR

The 192 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 10, 2022Scott John K Jr.DirectorBuy3,260Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • John K. Scott Jr.SC 13D/A, 8 filings Apr 22, 2022 to Feb 5, 202479
  • Irwin Allen BainSC 13G/A, 3 filings Oct 6, 2022 to Jul 3, 202380

SEC filer profile

How NAVIDEA BIOPHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNAVIDEA BIOPHARMACEUTICALS, INC.1
  • CIK0000810509
  • Employer ID (EIN)31-10800911
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4995 Bradenton Avenue, Suite 240, Dublin, OH 430171
  • Phone61479375001
  • Shares outstanding100,084,385 as of Nov 10, 202312
  • Public float$14.3M as of Jun 30, 20224
  • On EDGAR sinceFeb 7, 19951
  • Filings1,465 in all: 4 (483), 8-K (336), 424B3 (76), 10-Q (60), 3 (49), EFFECT (43), POS AM (37), DEF 14A (27)1
    All 57 form types

    CORRESP (26), SC 13D/A (26), UPLOAD (25), 10QSB (23), 4/A (22), 10-K (18), S-8 (15), CT ORDER (14), PRE 14A (12), S-3 (12), SC 13G/A (12), 424B5 (11), S-8 POS (11), SC 13G (11), DEFA14A (10), 8-K/A (9), S-1/A (8), S-3/A (8), 10KSB (6), S-1 (6), SD (6), ARS (5), SB-2 (5), SC 13D (5), PRER14A (4), 10-K/A (3), 10QSB/A (3), 15-12G (3), 8-A12G/A (3), NT 10-K (3), REGDEX (3), 10KSB40 (2), 25-NSE (2), 8-A12B (2), AW (2), DEFM14A (2), NT 10-Q (2), PREM14A (2), SB-2/A (2), 10-K405 (1), 10-K405/A (1), 10KSB/A (1), 424B4 (1), 8-A12G (1), CERT (1), CERTNYS (1), D (1), FWP (1), REGDEX/A (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Oct 5, 2023
    Latest 8-K (8-K) Dec 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80